BIOSTAR PHARM-B (02563) Reports Interim Results with Net Loss Narrowing 50.8% to RMB 26.596 Million
Stock News
Yesterday
BIOSTAR PHARM-B (02563) has announced its interim results for 2026, recording revenue of RMB 36.635 million, a year-on-year increase of 147.8%. Gross profit reached RMB 34.08 million, up 147.9% compared to the same period last year.
The company reported a net loss of RMB 26.596 million for the period, narrowing by 50.8% year-on-year, with a loss per share of RMB 0.07. The significant revenue growth was primarily driven by the continued expansion of market coverage for its product, Utidelone Injection, which boosted product sales volume during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.